Crinetics Pharmaceuticals Inc (CRNX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

10222 BARNES CANYON ROAD, BLDG. #2 SAN DIEGO, CA 92121

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing CRN04777, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for hyperinsulini® as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company's drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company

Data as of 2021-08-02 09:02:09 -0400
Market Cap675.929 Million Shares Outstanding37.593 Million Avg 30-day Volume115.984 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.48217 52-week High/Low21.64 / 11.61 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -27.1884
Data provided by IEX Cloud
View SEC Filings from CRNX instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 2 0.0% 1 (0.06%) 1 (0.06%) 0.0%
Funds Holding: 80 86 -6.98% 25 (1.47%) 31 (1.8%) -19.35%
13F shares: 30.689 Million 30.426 Million 0.86% 16.113 Million 15.978 Million 0.84%
% Ownership 93.2175 92.4184 0.86% 48.9411 48.5337 0.84%
New Positions: 5 20 -75.0% 1 10 -90.0%
Increased Positions 27 33 -18.18% 9 12 -25.0%
Closed Positions 11 6 83.33% 7 5 40.0%
Reduced Positions 26 15 73.33% 8 4 100.0%
Total Calls
Total Puts 17.868 Thousand
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CRNX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CRNX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

15 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

15 Thousand total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FUST MATTHEW K

  • Director
39,628 2021-07-26 4

WIERENGA WENDALL

  • Director
17,500 2021-06-22 1

NICHOLS WESTON

  • Director
17,500 2021-06-22 1

OKEY STEPHANIE

  • Director
17,500 2021-06-22 1

BEDROSIAN CAMILLE L

  • Director
17,500 2021-06-22 3

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

EDELMAN JOSEPH

  • 10% Owner
3,963,517 2021-04-08 1

KRASNER ALAN SETH CHIEF MEDICAL OFFICER

  • Officer
125,000 2021-02-26 2

WILSON MARC CFO AND SECRETARY

  • Officer
114,000 2021-02-26 2

STRUTHERS RICHARD SCOTT PRESIDENT & CEO

  • Officer
  • Director
294,000 2021-02-26 2

MADAN AJAY CHIEF DEVELOPMENT OFFICER

  • Officer
131,000 2021-02-26 2

KALDOR STEPHEN W

  • Director
0 2020-06-19 0

VIVO CAPITAL VIII, LLC

VIVO CAPITAL FUND VIII, L.P.

VIVO CAPITAL SURPLUS FUND VIII, L.P.

  • 10% Owner
No longer subject to file 2020-04-15 0

VIVO CAPITAL VIII, LLC

VIVO CAPITAL FUND VIII, L.P.

VIVO CAPITAL SURPLUS FUND VIII, L.P.

VIVO OPPORTUNITY, LLC

VIVO OPPORTUNITY FUND, L.P.

  • 10% Owner
3,266,090 2020-03-09 0

5AM VENTURES IV, L.P.

5AM CO-INVESTORS IV, L.P.

5AM PARTNERS IV, LLC

ROCKLAGE SCOTT M

DIEKMAN JOHN D

SCHWAB ANDREW J.

  • FORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDER
No longer subject to file 2019-06-21 0

NIELSEN JACK

  • Director
0 2019-06-21 0

VERSANT VENTURE CAPITAL V, L.P.

VERSANT AFFILIATES FUND V, L.P.

VERSANT OPHTHALMIC AFFILIATES I, L.P.

VERSANT VENTURE CAPITAL V (CANADA), LP

VERSANT VENTURES V, LLC

VERSANT VENTURES V (CANADA), L.P.

  • 10% Owner
2,876,688 2019-02-04 0

VERSANT VENTURE CAPITAL V, L.P.

VERSANT AFFILIATES FUND V, L.P.

VERSANT OPHTHALMIC AFFILIATES I, L.P.

VERSANT VENTURE CAPITAL V (CANADA), LP

  • 10% Owner
6,298,477 2018-07-20 0

VIVO CAPITAL VIII, LLC

VIVO CAPITAL, LLC

VIVO CAPITAL FUND VIII, L.P.

VIVO CAPITAL SURPLUS FUND VIII, L.P.

VIVO OPPORTUNITY, LLC

VIVO OPPORTUNITY FUND, L.P.

  • 10% Owner
10,035,939 2018-07-20 0

VIVO CAPITAL VIII, LLC

VIVO CAPITAL, LLC

VIVO CAPITAL FUND VIII, L.P.

VIVO CAPITAL SURPLUS FUND VIII, L.P.

  • 10% Owner
54,711 2018-07-17 0

FREEMAN MASON

  • Director
0 2018-07-17 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VI LLC

  • 10% Owner
0 2018-07-17 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

FUST MATTHEW K - Director

2021-07-27 20:00:21 -0400 2021-07-26 M 5,000 $1.91 a 17,536 direct yes -0.1135 -0.3405 2.0431 3 -0.5675 4

FUST MATTHEW K - Director

2021-07-27 20:00:21 -0400 2021-07-26 M 5,000 d 27,092 direct yes

FUST MATTHEW K - Director

2021-07-27 20:00:21 -0400 2021-07-26 S 5,000 $19.59 d 12,536 direct -0.1135 -0.3405 2.0431 3 -0.5675 4

FUST MATTHEW K - Director

2021-07-20 17:00:32 -0400 2021-07-19 M 5,000 $1.91 a 17,536 direct yes -0.3544 -10.7848 1.1646 3 -10.7848 6

FUST MATTHEW K - Director

2021-07-20 17:00:32 -0400 2021-07-19 M 5,000 d 32,092 direct yes

FUST MATTHEW K - Director

2021-07-20 17:00:32 -0400 2021-07-19 S 5,000 $19.50 d 12,536 direct -0.3544 -10.7848 1.1646 3 -10.7848 6

FUST MATTHEW K - Director

2021-07-13 17:00:31 -0400 2021-07-12 M 5,000 $1.91 a 17,536 direct yes -0.1014 0.1014 1.8246 5 -1.3685 4

FUST MATTHEW K - Director

2021-07-13 17:00:31 -0400 2021-07-12 M 5,000 d 37,092 direct yes

FUST MATTHEW K - Director

2021-07-13 17:00:31 -0400 2021-07-12 S 5,000 $20.71 d 12,536 direct -0.1014 0.1014 1.8246 5 -1.3685 4

WIERENGA WENDALL - Director

2021-06-23 17:00:30 -0400 2021-06-22 A 17,500 a 17,500 direct

OKEY STEPHANIE - Director

2021-06-23 17:00:26 -0400 2021-06-22 A 17,500 a 17,500 direct

FUST MATTHEW K - Director

2021-06-23 17:00:17 -0400 2021-06-22 A 17,500 a 17,500 direct

NICHOLS WESTON - Director

2021-06-23 17:00:28 -0400 2021-06-22 A 17,500 a 17,500 direct

BEDROSIAN CAMILLE L - Director

2021-06-23 17:00:21 -0400 2021-06-22 A 17,500 a 17,500 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 22:15:04 UTC -0.3016 0.3816 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 21:45:03 UTC -0.3235 0.4035 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 21:15:03 UTC -0.3235 0.4035 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 20:45:03 UTC -0.3235 0.4035 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 20:15:04 UTC -0.3235 0.4035 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 19:45:04 UTC -0.3822 0.4622 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 19:15:03 UTC -0.3822 0.4622 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 18:45:03 UTC -0.3466 0.4266 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 18:15:03 UTC -0.3466 0.4266 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 17:45:03 UTC -0.3466 0.4266 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 17:15:03 UTC -0.3466 0.4266 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 16:45:02 UTC -0.2985 0.3785 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 16:15:03 UTC -0.2985 0.3785 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 15:45:03 UTC -0.2985 0.3785 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 15:15:02 UTC -0.2985 0.3785 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 14:45:02 UTC -0.2616 0.3416 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 14:15:04 UTC -0.2616 0.3416 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 13:45:04 UTC -0.2616 0.3416 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 13:15:03 UTC -0.2616 0.3416 150000
CRINETICS PHARMACEUTICALS IN CRNX 2021-08-05 12:45:03 UTC -0.2616 0.3416 150000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund CRNX -7.0 shares, $-102.9 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund CRNX -4.0 shares, $-58.8 2020-03-31 N-PORT

Elevate your investments